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TO: Managed Care Entities 
FROM: Daniel Tsai, Assistant Secretary for MassHealth  
RE: Prior Authorization and Utilization Management for Suboxone® 
(buprenorphine/naloxone) 
Background  
To facilitate the provision of medically necessary medication to treat substance use disorders, 
EOHHS is establishing the following requirements effective immediately.  
Utilization Management including Prior Authorization for Suboxone® 
(buprenorphine/naloxone) 
MassHealth Managed Care Entities (MCEs), including Managed Care Organizations (MCOs), 
Accountable Care Partnership Plans (ACPPs), One Care plans, Senior Care Options (SCOs), and the 
Massachusetts Behavioral Health Partnership (MBHP) must provide access to at least one 
buprenorphine/naloxone treatment at Suboxone® equivalent doses of 24 mg/day or less without 
prior authorization.  
While MCEs may continue to impose quantity limits on buprenorphine/naloxone treatments, any 
such quantity limits must accommodate this rule, regardless of dosage strength. Therefore, if an 
MCE imposes quantity limits, the MCE must still allow for up to a total daily dose equal to or less 
than 24 mg without prior authorization.  
MassHealth Website 
This bulletin is available on the MassHealth website at www.mass.gov/masshealth-provider-
bulletins. 
To sign up to receive email alerts when MassHealth issues new bulletins and transmittal letters, 
send a blank email to join-masshealth-provider-pubs@listserv.state.ma.us. No text in the body or 
subject line is needed. 
Questions 
If you have any questions about the information in this bulletin, please contact the MassHealth 
Customer Service Center at (800) 841-2900, email your inquiry to providersupport@mahealth.net, 
or fax your inquiry to (617) 988-8974. 
 
